- Veracyte (VCYT, Financial) to present eight abstracts at the ASCO annual meeting, showcasing findings from Decipher Prostate and Bladder genomic classifiers.
- Studies reveal insights into treatment response for prostate and bladder cancer patients based on molecular tumor characteristics.
- Key findings include a 43% reduction in risk of death for certain prostate cancer patients using docetaxel.
Veracyte, Inc. (VCYT), a leading cancer diagnostics company, has announced the presentation of eight abstracts at the American Society of Clinical Oncology (ASCO) annual meeting. These studies leverage data from the company's Decipher Prostate and Decipher Bladder genomic classifiers, focusing on urologic cancers' molecular makeup.
The highlight of the presentation includes a study involving metastatic prostate cancer patients, revealing that those with PTEN-inactive tumors saw a 43% reduction in mortality risk when treated with docetaxel and standard androgen deprivation therapy (ADT), according to the Decipher Prostate GRID's transcriptome classification. This finding is crucial for tailoring chemotherapy interventions, as PTEN-active tumors showed no such benefit.
Additionally, the Decipher Bladder GRID study evaluates a non-standard treatment approach for muscle-invasive bladder cancer (MIBC), using Sacituzumab Govitecan combined with Pembrolizumab. This neoadjuvant strategy is followed by bladder-sparing procedures and maintenance therapy, showing promising safety and efficacy results. Molecular subtypes, identified through the study, highlight potential predictive markers for treatment response.
Veracyte's pioneering research aims to foster more personalized cancer care by harnessing genomic insights, potentially refining therapeutic approaches and enhancing patient outcomes in prostate and bladder cancer management.